Fzata, Inc.
Fzata is dedicated to expanding safety, efficacy, and access for therapeutic biologics through innovative oral biologics leveraging BioPYM platform. Their mission is to develop first-in-class live yeast medicines for GI diseases and gut-brain axis disorders, aiming to revolutionize biologic delivery with no needles, no infusions, and no refrigeration, while ensuring safety and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
Fzata, Inc.
Products
FZ002 (live biotherapeutic yeast candidate for Clostridioides difficile)
A first-in-class live yeast biotherapeutic candidate engineered to produce therapeutic proteins in the gut to treat C. difficile infection; advanced through preclinical studies, cGMP manufacturing, and clinical trial agreements toward IND/Phase 1 readiness.
FZ006 (oral biologic candidate for visceral pain/IBD-related indications)
An investigational oral live biotherapeutic program described as targeting visceral pain and inflammatory bowel disease–related indications, supported by grant funding and development planning.
FZ002 (live biotherapeutic yeast candidate for Clostridioides difficile)
A first-in-class live yeast biotherapeutic candidate engineered to produce therapeutic proteins in the gut to treat C. difficile infection; advanced through preclinical studies, cGMP manufacturing, and clinical trial agreements toward IND/Phase 1 readiness.
FZ006 (oral biologic candidate for visceral pain/IBD-related indications)
An investigational oral live biotherapeutic program described as targeting visceral pain and inflammatory bowel disease–related indications, supported by grant funding and development planning.
Services
Collaborative research and co-development partnerships
Partnerships with biotech and pharmaceutical firms for joint research, co-development, and access to platform capabilities to accelerate biologic candidate development.
Clinical development collaboration and trial enablement
Engagements to support clinical trial initiation through trial agreements and IND-enabling work for platform candidates.
Collaborative research and co-development partnerships
Partnerships with biotech and pharmaceutical firms for joint research, co-development, and access to platform capabilities to accelerate biologic candidate development.
Clinical development collaboration and trial enablement
Engagements to support clinical trial initiation through trial agreements and IND-enabling work for platform candidates.
Expertise Areas
- Oral live biotherapeutics
- Biologic antibody engineering and multi-specific formats
- Gastrointestinal therapeutics and gut-targeted delivery
- Infectious disease therapeutics (Clostridioides difficile)
Key Technologies
- Recombinant probiotic yeast expression systems
- Plug-and-play genomic insertion constructs
- Lyophilization for live biologics
- Oral capsule delivery systems for GI targeting